Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

February 15, 2006 at 2:30 PM

Richland’s IsoRay starts year with cash

The Richland company that makes radioactive “seeds” that can be inserted into solid tumors to treat cancer is touting a banner start to the year.

IsoRay Medical said it closed a $6 million private funding round at the end of January and has since raised more than $1.3 million through a new placement opened Feb. 1 to accommodate excess demand from investors.

It also signed a licensing agreement with a Belgian company that IsoRay says will reduce manufacturing and production costs of Cesium-131, the radioactive isotope it makes to treat prostate cancer. The collaborator, International Brachytherapy, can produce polymer seeds, which IsoRay CEO Roger Girard said offer advantages over the titanium seeds his company currently manufactures.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►